Search Results for keywords:"debarment"

The Food and Drug Administration (FDA) has withdrawn a previous notice regarding the debarment of Yong Sheng Jiao, which was published on December 5, 2024. The initial notice contained incorrect information about the reasons for debarment and left out revised language. A corrected version of the notice will be published separately in the same edition of the Federal Register. This action was taken to ensure the accuracy of the official record.

The Federal Communications Commission (FCC) has issued a notice suspending Moshe Schwartz from participating in the E-Rate Program and all universal service support mechanisms. Debarment proceedings are also being initiated against him. Individuals with contracts related to the schools and libraries support program involving Mr. Schwartz can challenge this suspension by submitting opposition requests within 30 days of receiving the suspension letter or by May 29, 2025, whichever comes first. The suspension ensures that Mr. Schwartz cannot benefit from the program while the debarment process is ongoing.

The Office of Research Integrity (ORI) found Liping Zhang, Ph.D., a former professor at Baylor College of Medicine, guilty of research misconduct. The violations involved falsifying images in unpublished manuscripts and grant applications funded by government health agencies like the NIH. Zhang did not contest the findings, which led to a two-year ban from participating in certain federal transactions and advisory roles. This decision took effect in early 2025 to safeguard the integrity of federal research endeavors.

The Food and Drug Administration (FDA) has issued an order under the Federal Food, Drug, and Cosmetic Act to permanently ban Sunrise Lee from working with any person or company that has a drug product application. This decision follows her felony conviction for racketeering related to the regulation of a drug product. Lee, who previously worked in a leadership role at Insys Therapeutics, was found guilty of participating in a conspiracy to bribe medical practitioners to prescribe a fentanyl-based drug called SUBSYS. Despite being notified of the proposed ban and given a chance to contest it, Lee did not respond, resulting in a waiver of her right to a hearing.

The Food and Drug Administration (FDA) has denied Yong Sheng Jiao's request for a hearing and has banned him from importing or offering to import any drugs into the United States for five years. This decision stems from Jiao's conviction for importing misbranded drugs, specifically dipyrone, by mislabeling them as sebacic acid. Jiao tried to argue that he was not responsible for the misbranding, claiming it was his supplier's fault, but the FDA maintained that his guilty plea in court provided enough basis for the ban. The FDA determined a five-year ban was appropriate after weighing the seriousness of his offense against the few mitigating actions he took.

The Office of Research Integrity (ORI) has found that Dr. Yibin Lin engaged in research misconduct while working as a postdoctoral fellow at the University of Texas Health Science Center. Dr. Lin knowingly falsified and plagiarized data in several published papers and submitted manuscripts, which led to their retraction. He even created fictitious author names to disguise his actions. As a consequence, Dr. Lin agreed to a voluntary ten-year exclusion from participating in any federal government contracts and serving in any advisory capacities to the Public Health Service.